Clinical trial for Multiple Sclerosis
Official title Cannabis (THC vs. CBD) in Multiple Sclerosis
ClinicalTrials.gov ID: NCT06261489
What this study is testing
What is THC?
THC is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for multiple sclerosis.
Also referred to as Tetrahydrocannabinol.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS). Participants will complete questionnaires and cognitive tests.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 26 to 59
You may be able to join if
- Age between 26 and 59 years inclusive.
- Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) [12]
- Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7.
- If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks.
- Sexually active men and women of child-bearing potential must agree to use adequate contraception.
You likely can't join if
- Major psychiatric disorder such as schizophrenia or bipolar disorder
- Major neurological disorder which could affect cognition such as dementia, traumatic brain injury.
- Seizure disorder
- Use of antipsychotic medication
- Use of benzodiazepines other than exclusively at night/bedtime
- Experienced a MS relapse in the last ninety (90) days.
See the full eligibility criteria
- Age between 26 and 59 years inclusive.
- Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) [12]
- Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7.
- If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks.
- Sexually active men and women of child-bearing potential must agree to use adequate contraception.
- Written informed consent.
- Major psychiatric disorder such as schizophrenia or bipolar disorder
- Major neurological disorder which could affect cognition such as dementia, traumatic brain injury.
- Seizure disorder
- Use of antipsychotic medication
- Use of benzodiazepines other than exclusively at night/bedtime
- Experienced a MS relapse in the last ninety (90) days.
- Current use of cannabis or CBM greater than 3x/week.
- Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study.
- Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes)
- Significant upper extremity disability that would interfere with the cognitive tests battery.
- Indwelling catheter use/urinary diversion
- Pregnant or Breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Calgary, Alberta, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 26 years to 59 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calgary, Alberta, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.